Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected adults,~* age ≥ 18 years,~* with a once-a-day ritonavir-boosted darunavir 800mg/j containing regimen plus 2 NRTI (≥ 6 months),~* virologically controlled (VL ≤ 50 cp/ml,~* ≥ 1 year,~* at least 2 VL spaced at least 3 months apart in the last 12 months) CD4 count ≥ 300/mm3 ≥ 6 months,~* virus sensible to darunavir and the used NRTI (pretreatment resistance genotypic test available) and~* with no history of virological failure (VL \> 200 cp/mL after ≥ 6 months under PI and/or used NRTI),~* no current opportunistic infection,~* renal clearance ≥ 60 mL/min if tenofovir is used,~* transaminases (SGOT, SGPT) plasma levels \< 2N,~* hemoglobin \> 11 g/dL,~* platelets count \> 150 000/mm3,~* negative pregnancy test in women with childbearing potential,~* informed written consent signed by both the investigator and the subject,~* national insurance scheme (article L1121-11 of the French Public Health code),~* no participation to any other clinical trial~Exclusion Criteria:~* HIV-2 infection,~* current antiretroviral therapy different from a once-a-day ritonavir-boosted darunavir 800mg/j containing regimen plus 2 NRTI,~* virus genotypically resistant to darunavir and the used NRTIs,~* history of virological failure (VL \> 200 cp/mL after ≥ 6 months under PI and/or used NRTI),~* irregular follow-up and/or history of lack of adherence to ART ≤ 12 months,~* current pregnancy,~* current opportunistic infection,~* associated treatment containing one or more drugs interacting with hepatic cytochromes,~* any addictive behaviors (alcohol consumption, drugs ...) likely to jeopardize the safety of the treatment and / or patient compliance and adherence to the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Darunavir 400mg/d (Type: EXPERIMENTAL): Tri-therapy containing Darunavir at dose of 400 mg/d.

Based on this trial design, predict the completion outcome and termination type (if applicable).